The information contained on this site is intended for institutional investors only, and is published strictly for informational purposes only without regard to the investment objective, financial situation or specific needs of any particular investor. The information is not intended for use by institutional investors in a jurisdiction where distribution or purchase is not authorized.
An institutional investor is one that falls within one or more of the following categories:
If you do not fall within at least one of the above categories you should not access the information contained in the site.
Baron Capital Management, Inc. makes reasonable efforts to ensure the material on the site is as accurate and timely as possible and that disruptions of service are minimal, Baron Capital Management, Inc. makes no warranty or guarantee concerning the availability of this site or the services or the accuracy of the information on it. In addition, the information contained on the site is in no way intended to constitute investment advice, an offer to sell, or a recommendation of any security or investment product. In fact, the products described herein may not be available to, or suitable for, all investors. You should consider, if appropriate, obtaining independent professional advice before making an investment decision. Please consider the charges, risks, expenses and investment objectives carefully before investing. Nothing on this site is intended to constitute legal or tax advice.
Please keep in mind that the opinions and views expressed through the content and commentaries published on the site are just that - opinions and views - and that they are published on the site for informational purposes only. In addition, views and opinions are based on the information available at the time and may not necessarily be shared by Baron Capital Management, Inc., or its employees, in general. As the investing environment changes, so could this information, and Baron Capital Management, Inc. has no responsibility to update it.
Past performance is not a guarantee of future performance. Investment results and principal value will fluctuate so shares, when redeemed, may be worth more or less than their original cost. Investors should be aware of the additional risks associated with investments in non-diversification, undervalued or overlooked companies and investments in specific industries. Additional risks may include those associated with investing in foreign securities, emerging markets, and companies with relatively small market capitalizations.
By selecting “I Agree” below, you confirm that you are an institutional investor or consultant to an institutional investor.
Baron offers accredited non-U.S. investors and qualified tax-exempt U.S. investors a range of options for investing in the equity market. Our investment vehicles include SICAV funds, separate accounts, collective investment trusts, and Baron USA Partners Fund.
This website may not be suitable for everyone, and if you are at all unsure whether an investment product referenced on this website will meet your individual needs, please seek professional advice before proceeding further with such product. Nothing on this website is, or is intended to be, an offer, advice, or an invitation to buy or sell any investments, in any jurisdiction where, or to anyone whom it would be unlawful to do so. By clicking “I Agree” below you acknowledge that you have read and understood this important information. Information on this website is issued by Baron Capital, Inc.
If you are a non-U.S. investor or qualified tax-exempt U.S. investor interested in our non-U.S. investment products, please contact Stephen Millar, VP, Head of EMEA, Institutional Sales | +44(0)7769 958822 | email@example.com
By selecting “I Agree” below, you confirm that you are an accredited non-U.S. investor or a qualified tax-exempt U.S. investor.
The link you have selected is not available within the Institution user experience. You will be switched to view this website as a Financial Advisor.
When you wish to view strategies again, click an 'Institution' link within the 'View As' menu or 'Strategies' in the footer.
Thank you for your email. We will respond as soon as possible.
as of 12/31/22
After a brutal nine months, stocks recovered somewhat in the fourth quarter. The small-cap Russell 2000 Growth Index advanced 4.13%. While the economy remained resilient, it was evident from many indicators, such as goods, energy, and rent prices, that inflation was cooling. There were signs of an economic slowdown on the horizon, stemming from aggressive central bank tightening. The market rallied in October and November, as interest rates declined, and the Federal Reserve chair laid the groundwork to slow the pace of its monetary tightening. However, the market gave back some gains in December as the Fed dampened hopes of interest rates cuts in 2023 and remained unified and steadfast in its goal of reducing inflation to 2% from December’s rate of 6.5%.
Against this backdrop, Baron Small Cap Fund increased in the quarter. Health Care, Information Technology (IT), and Industrials holdings contributed the most to performance. Investments within Consumer Staples detracted. Appreciation within Health Care was led by third largest contributor DexCom, Inc. Inspire Medical Systems, Inc. was another noteworthy contributor after shares of this medical device company rose on a beat and a raise. Gains within IT were led by top contributor Gartner, Inc. Industrials benefited from share price gains of second largest contributor Vertiv Holdings Co. Consumer Staples lost ground on weakness in the share price of facial treatment provider The Beauty Health Company.
The market is off to a good start in 2023, buoyed by a healthy economy highlighted by low unemployment and stable and solid consumer spending, declining inflation, and market expectations that the Fed is near the end of the rate hiking cycle.
The issue is that the Fed remains strident in its fight against inflation. It has posited short rates will rise to over 5% and remain there for an extended period. It remains focused on reducing “core” inflation, or the pace of wage growth, which will likely be difficult to reverse given tight labor markets. It is probably unnerved by the markets’ rise. We expect the Fed to continue to browbeat investors in the effort to slow down the economy, induce unemployment and reduce wage pressure, which it views as necessary. Higher rates will impact growth. Leading indicators point to a slowdown, and we hear that from the management teams of our holdings. However, we do not know if the slowdown or recession will be short-lived and shallow or longer and more severe. That’s the $64,000 question.
We own a portfolio of well-managed, high-quality companies. They are leaders in their niches, with strong competitive advantages. We believe they have great growth opportunities based on their positioning and well-established business plans. We underwrite significant long-term growth, which we do not believe is reflected in current trading prices where the market is presently focused. That will change.
as of 12/31/22
as of 12/31/22
When reviewing performance attribution on our portfolio, please be aware that we construct the portfolio from the bottom up, one stock at a time. Each stock is included in the portfolio if it meets our rigorous investment criteria. To help manage risk, we are aware of our sector and security weights, but we do not include a holding to achieve a target sector allocation or to approximate an index. Our exposure to any given sector is purely a result of our stock selection process.
as of 12/31/22
Baron Small Cap Fund (Institutional Shares) was up 4.24% in the fourth quarter, performing roughly in line with the Russell 2000 Growth Index as positive stock selection was mostly offset by cash exposure in a favorable market environment.
Health Care investments added significant value during the quarter, with most of the strength coming from diabetes management pioneer DexCom, Inc. and sleep apnea device manufacturer Inspire Medical Systems, Inc. DexCom was a top contributor in response to solid third quarter earnings, proposed Medicare coverage of its continuous glucose monitoring device for use by non-intensive insulin type 2 patients, and FDA approval of the company's seventh generation device, the G7. Inspire’s shares were bolstered by above-consensus third quarter financial results with revenue increasing more than 70% year-over-year. Management also raised guidance again for full-year revenue. Minimal exposure to lagging health care services, biotechnology, health care supplies, and pharmaceutical stocks together with outperformance of weighing instruments provider Mettler-Toledo International, Inc. also boosted relative results. Mettler’s shares were up after quarterly results and full-year guidance surprised to the upside due to solid performance in China as well as the Laboratory and Industrial segments. Favorable stock selection in Financials, Information Technology, and Consumer Discretionary also contributed to relative gains thanks in large part to noteworthy returns from global investment bank Houlihan Lokey, Inc., syndicated research provider Gartner, Inc., and fitness center operator Planet Fitness, Inc.
Adverse stock selection in Industrials and Consumer Staples along with lack of exposure to the top performing Energy sector mostly offset the above-mentioned gains. Weak stock selection in Industrials, owing largely to declines from staffing firm ASGN Incorporated and cryogenic technology and equipment leader Chart Industries, Inc., was partially offset by higher exposure to this better performing sector. ASGN’s shares fell on investor concerns about possible economic slowdown. We believe investors do not fully recognize how well ASGN is positioned given its exposure to sectors with favorable long-term secular growth trends. Chart’s share price reacted negatively to the Howden acquisition announcement as the amount of debt needed to fund the transaction spooked investors. We believe the benefits of the acquisition (cost synergies and improved margins, increased aftermarket percentage, and enhanced manufacturing footprint to serve the world’s clean energy needs) outweigh the execution risks. Performance in Consumer Staples was hindered by skin care treatment leader The Beauty Health Company, whose shares fell after announcing disappointing guidance for the remainder of the year due to uncertainty regarding the pace of recovery in China coupled with mounting foreign currency headwinds. We remain excited about the future of Beauty Health, as the company continues its global rollout of HydraFacial machines and grows utilization and brand awareness while increasing the profit margins.
as of 12/31/22
Baron Small Cap Fund (Institutional Shares) declined 31.05% for the year, trailing the Russell 2000 Growth Index by 469 basis points due to stock selection and differences in sector/sub-industry weights.
Cash exposure in a down market along with favorable stock selection in Financials, Information Technology (IT), Real Estate, and Communication Services added the most value. Strength in Financials came from specialty insurer Kinsale Capital Group, Inc., whose shares outperformed after reporting above-consensus financial results as market conditions and pricing trends remained favorable. Positive stock selection in IT was largely due to the outperformance of syndicated research provider Gartner, Inc. and process automation software leader Aspen Technology, Inc. Gartner was the largest contributor after the company’s quarterly financial results consistently exceeded Street estimates during the year. Growth in the research business compounded at double-digit levels, led by the company’s GBS segment, which is benefiting from a multi-year investment cycle. Aspen’s shares were up over 20% as organic trends continued to improve, with annual contract value growing 7.5% in the latest period. The company also closed a transformative deal with industrial equipment manufacturer Emerson. Performance in Real Estate and Communication Services was bolstered by temperature-controlled warehouse operator Americold Realty Trust and media company Liberty Media Corporation – Liberty Formula One, respectively. Americold’s shares outperformed the broader market due to increased optimism from management that labor, occupancy, and cash flow could soon begin to improve, while Liberty Formula One’s stock was aided by excellent financial results and excitement surrounding the company’s advantageous new broadcasting deal with ESPN.
The above-mentioned gains were undone by weak stock selection in Industrials and Consumer Discretionary coupled with lack of exposure to the top performing Energy sector. Adverse stock selection in Industrials was responsible for much of the relative shortfall, as wholesale landscape supplies distributor SiteOne Landscape Supply, Inc. and composite decking manufacturer Trex Company, Inc. were hurt by concerns about a housing-related slowdown negatively impacting their businesses into 2023. Insights and analytics leader Clarivate Plc and data center equipment and services provider Vertiv Holdings, LLC also weighed on performance in the sector. Housing market volatility also contributed to weakness in the Consumer Discretionary sector, where hard surface retailer Floor & Decor Holdings, Inc. and residential insulation installer Installed Building Products, Inc. were down sharply. Performance in the sector was also hampered by automotive products manufacturer Holley Inc. and corporate daycare provider Bright Horizons Family Solutions, Inc. Holley’s stock declined on disappointing results and lowered guidance due to microchip shortages and other supply-chain challenges that prevented it from building and shipping many of its most popular products. Results were also impacted by a sell-down of reseller inventories due to macroeconomic uncertainty. Bright Horizons shares were down as labor shortages are exacerbating the time needed to backfill center enrollment lost during the pandemic.
Investors should consider the investment objectives, risks, and charges and expenses of the investment carefully before investing. The prospectus and summary prospectuses contain this and other information about the Funds. You may obtain them from the Funds’ distributor, Baron Capital, Inc., by calling 1-800-99BARON or visiting www.BaronFunds.com. Please read them carefully before investing.
The performance data quoted represents past performance. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate; an investor's shares, when redeemed, may be worth more or less than their original cost. The Fund’s transfer agency expenses may be reduced by expense offsets from an unaffiliated transfer agent, without which performance would have been lower. Current performance may be lower or higher than the performance data quoted.
Risks:All investments are subject to risk and may lose value.
The discussion of market trends is not intended as advice to any person regarding the advisability of investing in any particular security. The views expressed on this page reflect those of the respective writer. Some of our comments are based on management expectations and are considered “forward-looking statements.” Actual future results, however, may prove to be different from our expectations. Our views are a reflection of our best judgment at the time and are subject to change at any time based on market and other conditions and Baron has no obligation to update them
Portfolio holdings are subject to change. Current and future portfolio holdings are subject to risk.
The index performance is not fund performance; one cannot invest directly into an index.